{"id":1113411,"date":"2021-06-21T10:42:59","date_gmt":"2021-06-21T08:42:59","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=1113411"},"modified":"2021-06-21T10:42:59","modified_gmt":"2021-06-21T08:42:59","slug":"accordo-bms-eisa-in-area-oncologia","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/accordo-bms-eisa-in-area-oncologia\/","title":{"rendered":"Accordo BMS-Eisa in area Oncologia"},"content":{"rendered":"<p>photo by <span class=\"attribution_field hide-sm hide-md\">Gerd Altmann<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>Bristol-Myers Squibb e Eisai hanno stipulato un accordo del valore di 3,10 miliardi di dollari per sviluppare e commercializzare congiuntamente un farmaco sperimentale contro il cancro. BMS verser\u00e0 a Eisai 650 milioni di dollari, comprese le spese di ricerca e sviluppo, oltre a una cifra che potr\u00e0 raggiungere al massimo 2,45 miliardi di dollari in milestones.<\/p>\n<p>Le due aziende svilupperanno e commercializzeranno congiuntamente il farmaco, che si chiama MORAb-202, in Asia, Europa, Stati Uniti e Canada.<\/p>\n<p>BMS ha stipulato a maggio un accordo da 1,56 miliardi di dollari con Agenus per sviluppare e commercializzare in modo esclusivo il suo farmaco sperimentale per trattamenti immuno-oncologici contro diverse malattie, incluso il cancro del polmone non a piccole cellule. La casa farmaceutica britannica punta molto sulle vendite di Opdivo, il suo farmaco per la cura di questo tipo di tumore, in un mercato attualmente dominato da Keytruda di MSD.<\/p>\n<p>Il farmaco di Eisai, MORAb-202, \u00e8 attualmente in fase iniziale di sviluppo per il trattamento dei tumori solidi, inclusi i tumori ovarici, polmonari e mammari.<\/p>\n<p>Fonte: <em>Daily Health Industry<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>photo by Gerd Altmann &nbsp; Bristol-Myers Squibb e Eisai hanno stipulato un accordo del valore di 3,10 miliardi di dollari per sviluppare e commercializzare congiuntamente un farmaco sperimentale contro il cancro. BMS verser\u00e0 a Eisai 650 milioni di dollari, comprese le spese di ricerca e sviluppo, oltre a una cifra che potr\u00e0 raggiungere al massimo 2,45 miliardi di dollari in milestones. Le due aziende svilupperanno e commercializzeranno congiuntamente il farmaco, che si chiama MORAb-202, in Asia, Europa, Stati Uniti e&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":1113606,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[2727,2709,3187],"class_list":["post-1113411","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-accordo","tag-bms","tag-eisai"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Accordo BMS-Eisa in area Oncologia - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accordo BMS-Eisa in area Oncologia - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by Gerd Altmann &nbsp; Bristol-Myers Squibb e Eisai hanno stipulato un accordo del valore di 3,10 miliardi di dollari per sviluppare e commercializzare congiuntamente un farmaco sperimentale contro il cancro. BMS verser\u00e0 a Eisai 650 milioni di dollari, comprese le spese di ricerca e sviluppo, oltre a una cifra che potr\u00e0 raggiungere al massimo 2,45 miliardi di dollari in milestones. Le due aziende svilupperanno e commercializzeranno congiuntamente il farmaco, che si chiama MORAb-202, in Asia, Europa, Stati Uniti e...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-21T08:42:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/06\/handshake-5768632_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1267\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Accordo BMS-Eisa in area Oncologia\",\"datePublished\":\"2021-06-21T08:42:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/\"},\"wordCount\":180,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/handshake-5768632_1920.jpg\",\"keywords\":[\"accordo\",\"bms\",\"eisai\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/\",\"name\":\"Accordo BMS-Eisa in area Oncologia - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/handshake-5768632_1920.jpg\",\"datePublished\":\"2021-06-21T08:42:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/handshake-5768632_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/handshake-5768632_1920.jpg\",\"width\":1920,\"height\":1267},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-bms-eisa-in-area-oncologia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accordo BMS-Eisa in area Oncologia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accordo BMS-Eisa in area Oncologia - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/","og_locale":"en_US","og_type":"article","og_title":"Accordo BMS-Eisa in area Oncologia - Frezza Partners","og_description":"photo by Gerd Altmann &nbsp; Bristol-Myers Squibb e Eisai hanno stipulato un accordo del valore di 3,10 miliardi di dollari per sviluppare e commercializzare congiuntamente un farmaco sperimentale contro il cancro. BMS verser\u00e0 a Eisai 650 milioni di dollari, comprese le spese di ricerca e sviluppo, oltre a una cifra che potr\u00e0 raggiungere al massimo 2,45 miliardi di dollari in milestones. Le due aziende svilupperanno e commercializzeranno congiuntamente il farmaco, che si chiama MORAb-202, in Asia, Europa, Stati Uniti e...","og_url":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/","og_site_name":"Frezza Partners","article_published_time":"2021-06-21T08:42:59+00:00","og_image":[{"width":1920,"height":1267,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/06\/handshake-5768632_1920.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Accordo BMS-Eisa in area Oncologia","datePublished":"2021-06-21T08:42:59+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/"},"wordCount":180,"image":{"@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/06\/handshake-5768632_1920.jpg","keywords":["accordo","bms","eisai"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/","url":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/","name":"Accordo BMS-Eisa in area Oncologia - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/06\/handshake-5768632_1920.jpg","datePublished":"2021-06-21T08:42:59+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/06\/handshake-5768632_1920.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2021\/06\/handshake-5768632_1920.jpg","width":1920,"height":1267},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/accordo-bms-eisa-in-area-oncologia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Accordo BMS-Eisa in area Oncologia"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1113411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=1113411"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1113411\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/1113606"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=1113411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=1113411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=1113411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}